Evogene Completes Sale of Lavie Bio to ICL

Jul 8, 2025
Evogene has finalized the sale of its subsidiary Lavie Bio to ICL, including the transfer of its MicroBoost AI platform.
Evogene Completes Sale of Lavie Bio to ICL

Evogene has completed the sale of its ag-biologicals subsidiary, Lavie Bio, to ICL, as announced in a press release. The transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, and advanced development programs.

In addition to these assets, Evogene has also transferred its MicroBoost AI for AG platform to ICL. This platform is designed to accelerate microbial product development in agriculture. The core personnel of Lavie Bio will also transition to ICL as part of the agreement.

Lavie Bio's existing strategic partnerships and commercial agreements remain under its ownership, potentially yielding future revenues for its shareholders. This transaction aligns with Evogene's strategy to unlock the value of its subsidiaries and technologies.

We hope you enjoyed this article

Free newsletter

AI Funding Brief

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.